v3.26.1
Acquisition of Biovire (Tables)
 6 Months Ended
Jun. 30, 2026
Business Combination [Abstract]  
Summary of Preliminary Purchase Price Allocation

The purchase price allocation is set forth in the table below and represents the Company’s fair value estimates related to the acquisition as of July 20, 2025.

 

 

Estimated fair value

 

Identifiable assets acquired

 

 

 

Cash

 

$

4,033

 

Current assets

 

 

2,565

 

Operating lease right-of-use assets

 

 

3,413

 

Property and equipment, net

 

 

16,610

 

Intangible assets

 

 

600

 

Total identifiable assets acquired

 

 

27,221

 

Liabilities assumed

 

 

 

Current liabilities

 

 

2,410

 

Operating lease liabilities, non-current portion

 

 

2,800

 

Long-term debt

 

 

3,000

 

Deferred tax liability

 

 

307

 

Other long-term liabilities

 

 

2,157

 

Total liabilities assumed

 

 

10,674

 

Net identifiable assets acquired

 

 

16,547

 

Goodwill

 

 

10,297

 

Total fair value of consideration paid

 

$

26,844